?Oclacitinib Maleate | USP/EP-Certified JAK1 Inhibitor | Bulk API for Veterinary Dermatology?
?Google Keywords?: Oclacitinib Maleate bulk supplier, JAK1 inhibitor API, pet allergy treatment, USP-certified veterinary drug

?? ?Product Overview?

Oclacitinib Maleate (CAS 1208319-27-0), also known as PF-03394197, is a selective Janus kinase 1 (JAK1) inhibitor widely used in veterinary medicine to treat allergic dermatitis and pruritus in dogs. It modulates cytokine signaling to reduce inflammation and itching, offering rapid symptom relief.

?? ?Key Advantages?

• ?High Purity?: ≥99% HPLC purity compliant with ?USP/EP? standards.

• ?Bulk Availability?: Custom batches from 1g to 25kg with COA, MSDS, and stability data.

• ?Formulation Flexibility?: White crystalline powder soluble in DMSO (≥20 mg/ml) for oral or topical use.

?? ?Applications?

• ?Canine Allergic Dermatitis?: First-line therapy for controlling itching and skin inflammation.

• ?Veterinary Pharmaceuticals?: Key ingredient in commercial antipruritic medications.

• ?Research?: Reference standard for JAK1 pathway studies in immunology.

?? ?Quality Compliance?

• Certified under ?USP/EP? guidelines with residual solvents <10ppm and heavy metals <20ppm.

• Stability tested for 24 months at -20°C in airtight, light-resistant packaging.

?? ?Market Trends?

The global veterinary dermatology market is projected to grow at ?6.5% CAGR (2025-2030)?, driven by rising demand for targeted therapies like Oclacitinib Maleate. Its selective JAK1 inhibition ensures efficacy with minimal systemic side effects.